Skip to content
Screener

Insmed INSM Other operating expenses

Other operating expenses at other companies

Solid Biosciences Inc. logo
Solid Biosciences Inc.SLDB
$57.38M+37.6%
Savara logo
SavaraSVRA
$38.99M+37.1%
ArriVent BioPharma, Inc. logo
ArriVent BioPharma, Inc.AVBP
$46.11M-30.9%
Theravance Biopharma logo
Theravance BiopharmaTBPH
$27.18M-8.9%
Upstream Bio, Inc. logo
Upstream Bio, Inc.UPB
$44.65M+37.0%
Rein Therapeutics Inc. logo
Rein Therapeutics Inc.RNTX
$5.23M-6.8%

Other financials

Income statement

See full
Revenue$425.5M+296%
Gross profit$358.3M+352%
Operating income-$1.5M+99.5%
Net income-$13.2M+95.9%
EPS (diluted)-$0.06+96.5%

Balance sheet

See full
Cash & equivalents$544.8M-57.6%
Total debt$579.9M+0.8%
Total equity$757.5M-39.4%
Total assets$2.1B-15.2%

Cash flow

See full
Operating cash flow-$88.8M+56.8%
CapEx$6.3M+79.6%
Free cash flow-$95.1M+54.5%

Valuation

See full
Market cap$28.95B+20.0%
Enterprise value$28.98B+23.8%
P/S25.4×-35.2×

Profitability

See full
Gross margin83.5%+7.7pp
Operating margin-73.9%-30.6pp
Net margin-76.9%-31.8pp
FCF margin-71%-28.6pp

Returns & leverage

See full
Return on equity-87.2%-27.3pp
Debt / equity0.8×+0.3×
Current ratio3.7×-3.0×

Where this comes from

Reported directly by Insmed in its filing.

Tagged under the XBRL concept us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther.

The source filing: Insmed’s 10-K, filed February 19, 2026.

Filed
Feb 19, 2026, 7:01 AM EST
Fiscal year
FY2025
Accession
0001104506-26-000009
Line itemYears Ended December 31, 2025 / $Years Ended December 31, 2025 / %Years Ended December 31, 2024 / $Years Ended December 31, 2024 / %Years Ended December 31, 2023 / $Years Ended December 31, 2023 / %
Stock-based compensation, net of nondeductible compensation(59,412)4.7%(12,574)1.4%2,443(0.3)%
Change in fair value of contingent consideration52,919(4.2)%19,253(2.1)%6,026(0.8)%
Asset acquisition18,217(2.4)%
Other729(0.1)%309865(0.1)%
Changes in unrecognized tax benefits
Effect of changes in tax laws or rates enacted in the current period
Other adjustments8,181(0.6)%9,564(1.1)%4,246(0.6)%
Provision for income taxes and effective tax rate$5,026(0.3)%$3,707(0.4)%$2,555(0.1)%

ITEM 16. FORM 10-K SUMMARY

FAQ

What is Insmed's other operating expenses?
Insmed (INSM) reported other operating expenses of -0.1% in Q4 2025.
What does other operating expenses mean?
Residual operating expenses not classified into specific categories, serving as a catch-all for miscellaneous operating costs.

Ask your AI about Insmed's other operating expenses.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude